VWR ($VWR) announced that it has acquired MESM Ltd., a provider of laboratory and medical equipment and ancillary supplies to clinical trials globally. VWR said that the acquisition will help the company in offering “end-to-end product and supply chain solutions." The financial terms and conditions of the deal have not been disclosed.
Kura Oncology ($KURA) announced that it has dosed its first patient in its Phase 1 clinical trial of KO-947, a selective small molecule inhibitor of extracellular-signal-regulated kinases 1 and 2 (ERK1/2). The Phase 1 trial of KO-947 is designed to determine the maximum tolerated dose in patients with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancies.